Drugs / Ginkgo biloba
Ginkgo biloba
also known as
EGb 761 · GBE · Gingko biloba · Ginkgo · Ginkgo biloba extract · GINKO BILOBA · Tebonin
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02386852 | Mar → Nov 2014 | — | Sunway University | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT02882438 | Jan 2016 → Sep 2020 | tinea pedis | Al-Azhar University | Unknown | No outcome recorded |
| Phase 1 | NCT01246804 | Nov 2010 → Mar 2011 | HIV infectious disease, cognitive impairment with or without cerebellar ataxia, depressive disorder | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00689858 | May 2007 → Jul 2008 | — | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00011063 | Feb → Apr 2001 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/23 trials · 1 missed | ||||||
| Phase 1/2 | NCT00029991 | Sep 2000 → Jul 2005 | intermittent vascular claudication | National Center for Complementary and Integrative Health (NCCIH) | Completed | Missed primary |
| Phase 1/2 | NCT00029679 | Sep 2000 → Jul 2005 | asthma | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 1/2 | NCT00010842 | Sep 1999 → Dec 2004 | multiple sclerosis | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02376114 | Aug 2011 → Feb 2014 | open-angle glaucoma | Maisonneuve-Rosemont Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00034021 | Jun 2002 → Sep 2004 | hypoactive sexual desire disorder | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00046891 | Dec 2002 → Oct 2006 | breast cancer, poisoning | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT01046292 | Jan 2010 → Feb 2015 | cognitive impairment with or without cerebellar ataxia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT00103012 | Jan 2005 → Jan 2011 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06771128 | Nov 2024 → Dec 2025 | nocturnal enuresis | Menoufia University | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 0 | NCT02465749 Background | May 2015 → Jun 2025 | retinitis pigmentosa | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1 | NCT03772418 Comparator | May 2018 → Jan 2020 | — | Al-Azhar University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00070954 Comparator | Feb 2003 → Jan 2005 | — | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 2 | NCT00841321 Comparator | Jan 2009 → Nov 2010 | CGF1, multiple sclerosis | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 3 | NCT02098330 Comparator | Mar → Dec 2014 | vestibular neuronitis | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00010803 Comparator | Oct 2000 → Apr 2008 | Alzheimer disease | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 3 | NCT01637168 Comparator | — | — | EMS | Withdrawn | No outcome recorded Stop: Business |
| — | NCT06772584 Comparator | Jan → Jul 2024 | nocturnal enuresis | Menoufia University | Completed | No outcome recorded |
| — | NCT01663467 Background | Sep 2014 → Sep 2016 | tinnitus | Seoul National University Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginkgobiloba | “Ginkgo biloba has been reported to increase maximal and pain-free walking distance among patients with PAD; however, the evidence is inconsistent.” PMID 18628657 ↗ Jul 200823“Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States.” NCT06772584 ↗ “Ginkgo biloba, a flavonoid-rich extract of leaves of the Ginkgo biloba tree” NCT00029679 ↗ “Ginkgo Biloba 120 mg twice daily for 14 days” NCT00103012 ↗ “Ginkgo Biloba in different dosage forms” NCT02882438 ↗ “Drug: Ginkgobiloba” NCT06772584 ↗ |
| Known as | EGb 761 | “The objective of this study was to compare the effects of 300 mg/d of Ginkgo biloba (EGb 761) versus placebo on treadmill walking time and related cardiovascular measures among...” PMID 18628657 ↗ Jul 2008 |
| Known as | GBE | “Ginkgo biloba extract (GBE), a naturally occurring substance from the ancient Chinese Ginkgo tree” NCT00034021 ↗ |
| Known as | Gingko biloba | “Gingko biloba is a complementary or alternative medication used for purported cognitive enhancing effects.” NCT00011063 ↗ |
| Known as | Ginkgo | “The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of...” NCT02376114 ↗ |
| Known as | Ginkgo biloba extract | “Ginkgo biloba extract (GBE), a naturally occurring substance from the ancient Chinese Ginkgo tree” NCT00034021 ↗ |
| Known as | GINKO BILOBA | “GINKO BILOBA Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States.” NCT06772584 ↗ |
| Known as | Tebonin | “Ginkgo Biloba (Tebonin®)” NCT01637168 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging.” PMID 20040554 ↗ Dec 2009 |
| Route | Oral | “supply of 60-mg capsules of ginkgo to take twice a day (at 8 A.M. and 8 P.M..)” NCT00011063 ↗ |